Navigation Links
Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
Date:12/16/2008

onstrated that the Intermezzo(R) 1.75 mg and 3.5 mg doses, when used at the time of a middle of the night awakening, significantly shortened the time for patients to return to sleep as compared to placebo, with no evidence of next day residual sedative effects with either dose. Further, when patients used the 3.5 mg dose, the study also indicated statistically significant improvements in total sleep time, sleep efficiency, subjective number of post-dose awakenings, sleep quality, level of refreshed sleep, and next day ability to function. Transcept believes that these are the lowest zolpidem doses that have been reported to be statistically superior to placebo in producing sleep.

The second Phase 3 clinical trial was a double-blind, placebo-controlled outpatient study in which 294 patients used either Intermezzo(R) 3.5 mg or placebo at home, at the time they awakened in the middle of the night and had difficulty returning to sleep. This Phase 3 clinical trial also met its primary endpoint of significantly reducing the time required for the patient to return to sleep versus placebo. After dosing and returning to sleep, patients in the outpatient study who were randomized to Intermezzo(R) also reported fewer subsequent awakenings and less time awake during the remainder of the night. There was no evidence of next day residual sedative effects after middle of the night use of Intermezzo(R) versus placebo.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the nigh
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... (PRWEB) March 25, 2015 An increase ... ingredients in all forms of food nutrients, regulatory changes ... a substantial rise in demand for natural astaxanthin over ... started to ramp up their capacities to satisfy the ... natural and synthetic source astaxanthin (used in nutraceuticals, aqua ...
(Date:3/25/2015)... March 25, 2015 Data from ... Mechanism of Action in Neuromuscular Diseases , ... Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of ... troponin activator tirasemtiv in the journal Neurotherapeutics. ... “Evidence of Effect” or hypothesis-generating clinical trial which ...
(Date:3/25/2015)... March 25, 2015 Researchers at ... nanoparticle technology that will enable broader and less ... diseases with a simple breath screen. The Minnesota-based ... U.S. Food and Drug Administration (FDA) approval process ... the innovative Nanoparticle Biomarker Tagging device. , Ancon ...
(Date:3/25/2015)...  The Technology Association of Georgia ... promotion and economic advancement of Georgia,s ... of its Top 40 Innovative Technology Companies in ... group at the 2015 Georgia Technology Summit (GTS) on ... TAG,S Top 40 Awards recognize Georgia ...
Breaking Biology Technology:Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 4
... carbon nanotubes more than doubles the growth rate of ... everything from lifesaving medications to sweeteners to dyes and ... to show that carbon nanotubes boost plant cell division ... . Mariya V. Khodakovskaya and colleagues explain that ...
... Ga., April 4, 2012  MiMedx Group, Inc. (OTCBB: MDXG), ... regenerative biomaterials and bioimplants processed from human amniotic membrane, ... revenue goal for the first quarter of 2012. The ... $3.6 million. The Company also reported ...
... SETAUKET, N.Y., April 4, 2012 Lixte Biotechnology Holdings, ... the United States Patent and Trademark Office for its ... homologs. Dr. John Kovach, founder and president ... certain types of skin lymphomas and many other HDACi ...
Cached Biology Technology:MiMedx Exceeds Revenue Goal for First Quarter of 2012 2Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 2Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 3
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Research Institute scientists has taken a significant step toward answering ... RNA enzymes that can replicate themselves without the help of ... indefinitely. The work was published on Thursday, January ... edition of the journal Science . In the ...
... Calif., January 9, 2009 -- Researchers at the ... that search algorithms used in digital communications can ... led by Giovanni Paternostro, M.D., Ph.D., was published ... PLoS Computational Biology . Using the stack ...
... unveil a novel "two-stage, approach for developing new energy ... emissions and create a cleaner economy during a policy ... York Ave. N.W. in Washington, D.C. , ... Mellon, the University of Minnesota, The Vermont Law School ...
Cached Biology News:Scripps scientists develop first examples of RNA that replicates itself indefinitely 2Scripps scientists develop first examples of RNA that replicates itself indefinitely 3Scripps scientists develop first examples of RNA that replicates itself indefinitely 4Digital communication technology helps clear path to personalized therapies 2Carnegie Mellon to unveil new sequestration plan 2
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
... Model 440 incorporates four channels of sophisticated ... easy-to-use instrument. Each channel consists of a ... lowpass filter, a highpass filter, a line ... control knob sets the amplifier parameters and ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... arm rapidly transfers a basket of plates between ... that are considerably faster than those of peltier ...
... is a four-channel general purpose laboratory amplifier. It ... sources which may have a large common-mode level ... a high gain/low noise amplifier, an input coupling ... offset control. A control knob sets the amplifier ...
Biology Products: